madman
Super Moderator
Dr. Lisa Faast breaks down a major FDA Category 1 update that compound pharmacies need to know about — Enclomiphene has officially been added to the Category 1 list
I explain why this is such a game-changer, what enclomiphene is used for (especially for men looking to naturally raise testosterone levels without injections or creams), and why I believe this move is going to significantly expand the compounding market. I also share exactly how I think compounding independent pharmacies should be positioning themselves right now to take advantage of this opportunity.
In this video, Lisa explains:
* What the FDA update means for compounders
* Why Enclomiphene is now clearly in the “green zone”
* How this impacts 503A compounding pharmacies
* Why Enclomiphene is becoming a major cash-pay opportunity
* How pharmacies can position themselves as the local expert
* Marketing and education strategies to grow this category
Enclomiphene is gaining attention as an oral option to help support healthy testosterone levels, and this FDA clarification could open the door for more awareness, prescribing, and patient demand.
If you’re a compound pharmacy owner, now is the time to educate your community and prepare for growth in this space.
Time Stamps
0:00 Intro
0:10 FDA Category 1 Update and GHK Clarification
0:46 Enclomiphene's Inclusion in Category 1
2:33 Pharmacy Marketing and Promotion Opportunities
3:34 Education and Community Engagement
*
